Skip to main content
micro-community-banner
 
  • Saved

made a Post

Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer - PubMed

High TMB and PD-L1 expression are predictive for benefit from ICB treatment in oncogene-driven NSCLCs. NSCLC harboring BRAF mutations demonstrated superior benefit from ICB that may be attributed to higher ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34376553/

  • Saved

made a Post

Anti-PD-(L)1 for KRAS-mutant advanced non-small-cell lung cancers: a meta-analysis of randomized-controlled trials - PubMed

doi: 10.1007/s00262-021-03031-1. Online ahead of print. 1 Service de Pharmacie, HUPSSD-APHP, 125, rue de Stalingrad, 93009, Bobigny, France. [email protected] 2 Service de Pneumologie, CHU d'Angers, Angers Cedex 9, France. 3 ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34378081/

  • Saved

from Pathologist Connect made a Post

A new publication by Yale Cancer Center highlights recent breakthrough therapies developed to treat non-small cell lung cancer.

Yale Cancer Center Perspective Highlights New Advances for NSCLC

A new publication by Yale Cancer Center highlights recent breakthrough therapies developed to treat non-small cell lung cancer (NSCLC). The goal of the study is to provide views on how ..... see more

Source : https://www.yalecancercenter.org/news-article/yale-cancer-center-perspective-highlights-new-advances-for-nsclc/

  • Saved

made a Post

Sotorasib: First Approval - PubMed

Sotorasib (LUMAKRAS ™ ) is a RAS GTPase family inhibitor being developed by Amgen for the treatment of solid tumours with KRAS mutations, including non-small cell lung cancer (NSCLC) and ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34357500/

  • Saved

made a Post

Inhibitors Targeting CDK9 Show High Efficacy against Osimertinib and AMG510 Resistant Lung Adenocarcinoma Cells - PubMed

Non-small cell lung cancer has a 5-year survival rate of less than 12-15%, calling for the development of additional therapeutic strategies to combat this disease. Here we tested the efficacy ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34359807/

  • Saved

made a Post

Short report: Performance evaluation of the Idylla™ KRAS and EGFR mutation tests on paraffin-embedded cytological NSCLC samples - PubMed

Our results confirm the conclusion of recent reports that the Idylla™EGFR assay is not suitable in a resistance to EGFR TKI setting, also not in our cytological NSCLC samples prepared ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34344387/

  • Saved

from Pathologist Connect made a Post

Nice to see this option on the Neogenomics online requisition.

  • Saved

from Pathologist Connect made a Post

Analysts expect blockbuster revenues in the coming years

How's Amgen's key KRAS launch looking? It's too early for meaningful sales, but expectations are riding high

It's only been about two months since Amgen's hot new KRAS inhibitor Lumakras won FDA approval, but it's clear the drug is already shouldering big expectations. While the company didn't ..... see more

Source : https://www.fiercepharma.com/marketing/how-s-amgen-s-key-kras-launch-looking-it-s-early-days-but-lumakras-gaining-steam-execs

  • Saved

made a Post

Emerging strategies to target RAS signaling in human cancer therapy - PubMed

RAS mutations (HRAS, NRAS, and KRAS) are among the most common oncogenes, and around 19% of patients with cancer harbor RAS mutations. Cells harboring RAS mutations tend to undergo malignant ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34301278/

  • Saved

made a Post

Lentiviral-driven discovery of cancer drug resistance mutations - PubMed

Identifying resistance mutations in a drug target provides crucial information. Lentiviral transduction creates multiple types of mutations due to the error-prone nature of the HIV-1 reverse transcriptase (RT). Here we ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34301758/

  • Saved

made a Post

Stopping the beating heart of cancer: KRAS reviewed - PubMed

It has taken four decades of research to see the first major breakthrough for KRAS-driven cancers. In particular, the last decade has seen a paradigm shift with the discovery of ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34303932/

  • Saved

from Pathologist Connect made a Post

Spotlight on KRAS G12C: Biomarker Testing Considerations in the NSCLC Landscape
/>

  • Saved

from Pathologist Connect made a Post

LabCorp launches KRAS mutation analysis for new lung cancer therapy

LabCorp launches diagnostic for new lung cancer therapy | WRAL TechWire

Editor's note: LimeLight is a new feature from WRAL TechWire offering another means of publishing noteworthy news. Be sure to check out more LimeLight worthy news at this link. BURLINGTON ..... see more

Source : https://www.google.com/amp/s/www.wraltechwire.com/2021/07/02/labcorp-launches-diagnostic-for-new-lung-cancer-therapy/

  • Saved

from Pathologist Connect made a Post

People living with lung cancer launch a social media takeover August 1

People living with lung cancer launch a social media takeover!

Los Angeles, CA, July 28, 2021 (GLOBE NEWSWIRE) -- Join dozens of patient advocates living with lung cancer and meet the researchers working to find better treatments for the disease ..... see more

Source : https://www.globenewswire.com/news-release/2021/07/28/2270065/0/en/People-living-with-lung-cancer-launch-a-social-media-takeover.html

  • Saved

made a Post

Immune checkpoint inhibitors in oncogene-addicted non-small cell lung cancer: a systematic review and meta-analysis - PubMed

In oncogene-addicted NSCLC (with the exception of KRAS -mutated), ICIs are usually administered at the failure of other treatment options, but administering single-agent immunotherapy in later disease phases may limit ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34295687/

  • Saved

made a Post

A retrospective observational study of the natural history of advanced non-small-cell lung cancer in patients with KRAS p.G12C mutated or wild-type disease - PubMed

doi: 10.1016/j.lungcan.2021.05.026. Online ahead of print. 1 Virginia Cancer Specialists, 8503 Arlington Blvd Suite 400, Fairfax, VA, 22031, USA; US Oncology Research, The Woodlands, TX, USA; Johns Hopkins School of ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34293517/

  • Saved

made a Post

Landscape of Biomarkers in Non-small Cell Lung Cancer Using Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry - PubMed

Comprehensive genomic profiling (CGP) and immunohistochemistry (IHC) are important biomarker tools used for patients with non-small cell lung cancer (NSCLC) given the expanding number of standard-of-care therapies that require companion ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34257540/

  • Saved

from Pathologist Connect made a Post

Emerging Therapies Expand Options in Lung Cancer

Emerging Therapies Expand Options in Lung Cancer

During the past 12 months, the treatment landscape for patients with non-small cell lung cancer has expanded dramatically with FDA approvals of the first drugs directed at KRAS G12C and ..... see more

Source : https://www.onclive.com/view/emerging-therapies-expand-options-in-lung-cancer

  • Saved

Commented on 's Post

EGFR and KRAS Mutations in Lung Parenchyma of Subjects With EGFR/KRAS Wild-Type Lung Adenocarcinoma - PubMed

The acquisition of driver mutations in non-tumoral cells appears to be very important during the carcinogenesis of adenocarcinoma (ADC). Recent studies suggest that cancer-related mutations may not necessarily be present ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34257550/

Show More Comments

  • 2 months 1 week
    Key Points • In the current study, researchers aimed to show the presence of EGFR or KRAS mutations in non-tumoral lung cells in patients with adenocarcinoma and negative mutational status. • Via Show More
  • Saved

made a Post

The genomic characteristics of different progression patterns in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors - PubMed

1 Department of Pulmonary, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China. 2 Department of Pathology, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China. 3 Department of Medicine ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/34268392/